This report is based on public company disclosures, filings and announcements reviewed by GSN; figures are as stated by the company and have not been independently verified.

The American Society for Radiation Oncology (ASTRO) Annual Meeting in Boston is not a place where companies typically unveil new products or announce blockbuster mergers. It is a gathering of clinicians, researchers, and scientists who pore over abstracts, looking for subtle shifts in how radiation therapy is delivered. For a diagnostics company like Veracyte (Nasdaq: VCYT), the conference is a different kind of arena. It is where the company must show that its genomic tests, which analyze the molecular biology of tumors, actually change the way doctors make life-altering treatment decisions. This week, Veracyte is stepping into that arena by announcing that eight studies leveraging its Decipher Prostate Genomic Classifier will be presented at the meeting.

The company said the presentations will cover a mix of oral sessions and posters, drawing from Phase II and III clinical trials, Genomic Research for Intelligent Discovery (GRID) research, and national real-world studies. The central theme, according to the company, is to examine the test’s prognostic value in assessing disease risk and its predictive value in identifying which patients might benefit from treatment intensification. This includes scenarios where doctors must decide whether to add androgen-deprivation therapy (ADT) to radiation. The studies are scheduled to run from September 27 to September 29, with additional information available through the ASTRO 2026 Annual Meeting program.

Veracyte says its molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. The company’s diagnostics platform combines broad genomic and clinical data, advanced bioinformatics and AI, and an evidence-generation engine to support innovation and pipeline development. Beyond the Decipher Prostate test, Veracyte’s portfolio includes the Afirma Genomic Sequencing Classifier test, the Prosigna Breast Risk of Recurrence test, the Decipher Bladder Genomic Classifier, and the TrueMRD Monitoring Test for MIBC. The company said its vision is to transform cancer care for patients around the world.

The thread connecting these eight studies is personalized care. Radiation therapy is a central part of prostate cancer treatment, but the side effects can be significant, and the long-term outcomes vary. By adding a genomic layer to the decision-making process, Veracyte is arguing that doctors can move away from a one-size-fits-all approach. The company’s medical director for Urology, Elai Davicioni, Ph.D., said the breadth of research being presented underscores the growing role of genomic information in helping clinicians navigate complex prostate cancer treatment decisions. Davicioni added that these presentations demonstrate how elucidating the molecular components of tumor biology may help personalize treatment decisions for patients across different stages of disease.

What this could become is a shift in how prostate cancer treatment decisions are made. If the data presented at ASTRO holds up under scrutiny, it could strengthen the case for the Decipher test as a routine tool in the radiation oncologist’s toolkit. Imagine a future where a patient’s risk score directly informs the intensity of their treatment, sparing low-risk patients from unnecessary intensification while intensifying treatment for those most likely to progress. Alternatively, if the data fails to show a clear link between genomic scores and clinical outcomes, the test could remain a niche tool, used by a subset of specialists rather than becoming broadly adopted. The signpost to watch will be the reaction of the radiation oncologists in the audience to the oral sessions, as they judge the clinical utility of the data.

To our eye, the strategy is a careful balancing act. Veracyte is not just presenting laboratory results; it is presenting real-world evidence and clinical trial data that must convince a skeptical community of clinicians. The inclusion of studies from national real-world data suggests the company is aware that controlled conditions do not always reflect the messy reality of clinical practice. The desk’s reading is that Veracyte is trying to build a broad body of evidence. By covering everything from post-prostatectomy salvage radiotherapy to secondary radiotherapy, the company is attempting to show that its test is relevant across different stages of the disease. If the data supports that, it could broaden the settings in which clinicians consider using the test.

What to watch are the specific findings from the oral presentations, particularly the NRG Oncology-RTOG 0534 analysis and the NRG GU002 results. These are clinical trial analyses, and the announcement itself does not disclose study findings, so the data they yield will be closely scrutinized by the medical community. The company said the presentations will highlight Decipher’s prognostic and predictive value, so the abstracts will be key. Investors and clinicians alike will be looking for statistical significance in the risk stratification and clear signals of benefit from treatment intensification. The poster sessions, including the national real-world analyses, will also provide important context on how the test performs outside of controlled clinical trials.

This is analysis and opinion from GSN’s AI newsdesk, based on the public documents listed below; it is not investment advice.

Sources